Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KROS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dose A KER-012 | Pulmonary Arterial Hypertension | Phase 2 · NCT05975905 | Terminated |
| Dose B KER-012 | Pulmonary Arterial Hypertension | Phase 2 · NCT05975905 | Terminated |
| Dose C KER-012 | Pulmonary Arterial Hypertension | Phase 2 · NCT05975905 | Terminated |
| KER-047 | Iron Deficiency Anemia | Phase 2 · NCT05927012 | Withdrawn |
| Rinvatercept | Duchenne Muscular Dystrophy | Phase 2 · NCT07704099 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KROS holds $259.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.5M/quarter from operations, an estimated runway of 91.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
Based on our current operating assumptions, we believe that our existing cash and cash equivalents will be sufficient to fund our projected liquidity requirements into the second half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KROS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock Portfolio Management LLC | Institution (13G, 5%+) | 1,813,870 | 9.24% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 1,671,343 | 8.52% | 2026-06-30 |
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 1,360,419 | 6.93% | 2026-03-31 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director · +576,944 options |
Insider | 440,708 | 2.25% | 2026-04-02 |
| Julius Knowles Director · +7,433 options |
Insider | 113,191 | 0.58% | 2026-06-04 |
| Annita Tanini Corp. Controller & VP, Finance |
Insider | 45,144 | 0.23% | 2026-08-18 |
| ORBIMED ADVISORS LLC Director |
Insider | 45,057 | 0.23% | 2025-11-21 |
| Carl L Gordon Director Includes shares also reported by ORBIMED ADVISORS LLC, counted once |
Insider | 45,057 | 0.23% | 2025-11-21 |
| Keith Regnante CHIEF FINANCIAL OFFICER · +60,000 options |
Insider | 39,261 | 0.20% | 2026-02-18 |
| Esther Cho Chief Legal Officer · +80,000 options |
Insider | 35,770 | 0.18% | 2026-08-18 |
| Lorena Raquel Lerner Chief Scientific Officer · +75,000 options |
Insider | 27,559 | 0.14% | 2026-08-18 |
| Jean Jacques Bienaime Director · +7,433 options |
Insider | 19,592 | 0.10% | 2026-08-17 |
Share count 19,624,374 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KROS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →